<DOC>
	<DOCNO>NCT00102505</DOCNO>
	<brief_summary>The purpose study determine dose limit toxicity maximum tolerate dose motexafin gadolinium administer docetaxel cisplatin patient Non-small Cell Lung Cancer . A cycle consist 3 week . During week 1 , patient receive MGd , docetaxel , cisplatin treatment follow 2 week without treatment . Eligible patient receive 1 2 dos MGd , depend cohort , single dose docetaxel cisplatin 75 mg/m² first week cycle . Additionally , tumor response evaluate end even numbered cycle ( 2 , 4 , 6 ) . Patients may stay study maximum 6 cycle .</brief_summary>
	<brief_title>A Study Motexafin Gadolinium ( MGd ) Combination With Docetaxel Cisplatin Treatment Non-Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Carcinoma , Bronchogenic</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Motexafin gadolinium</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>≥ 18 year old ECOG score 0 , 1 , 2 Histologically confirm diagnosis nonsmall cell lung cancer Laboratory value demonstrate inadequate function follow : Bone marrow Kidneys Liver Peripheral neuropathy Grade 2 high Greater 2 prior chemotherapy regimen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>Non-Small Cell Lung Cancer</keyword>
	<keyword>Lung Cancer</keyword>
	<keyword>Metastatic lung cancer</keyword>
	<keyword>Inoperable lung cancer</keyword>
	<keyword>Advanced lung cancer</keyword>
	<keyword>Large-cell lung cancer</keyword>
	<keyword>Adenocarcinoma , lung</keyword>
	<keyword>Squamous cell carcinoma , lung</keyword>
	<keyword>Squamous cell lung cancer</keyword>
	<keyword>Large cell carcinoma , lung</keyword>
	<keyword>Bronchogenic</keyword>
</DOC>